All Updates

All Updates

icon
Filter
Partnerships
Verge Genomics collaborates with AstraZeneca subsidiary to discover drugs for rare neurodegenerative and neuromuscular diseases
AI Drug Discovery
Sep 8, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
AI Drug Discovery

AI Drug Discovery

Sep 8, 2023

Verge Genomics collaborates with AstraZeneca subsidiary to discover drugs for rare neurodegenerative and neuromuscular diseases

Partnerships

  • California-based AI biotechnology company Verge Genomics has entered a multi-target partnership with Alexion, a subsidiary of AstraZeneca, to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.

  • The four-year agreement will see Verge receive up to USD 42 million that comprises an upfront fee, equity, and near-term payments, with a potential deal value of USD 840 million plus potential royalties.

  • The collaboration will leverage Verge's CONVERGE platform, which combines human tissue datasets with AI, to identify and validate therapeutic targets for rare diseases. Alexion will have the option to license and advance successful targets through clinical development and commercialization. Through this partnership, AstraZeneca will also take an equity position in Verge Genomics.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.